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Acetyl salicylic acid (ASA), a non-steroidal anti-inflammatory 
drug (NSAID) is widely used for its analgesic, antipyretic, anti-
inflammatory and anti-thrombotic action. The aim of the present 
study was to investigate the pharmaceutical equivalence of two 
brands of dispersible ASA tablets marketed in Oman. Two different 
brands of dispersible ASA tablets (300mg) were purchased from 
the retail pharmacy outlets and their pharmaceutical quality were 
assessed by using in-vitro tests as per the British Pharmacopoeia 
(BP) and unofficial standards as recommended by the 
manufacturers. The assessment of tablets included the evaluation 
of uniformity of weight and diameter, friability, crushing strength, 
disintegration and chemical assay by volumetric titration and 
colorimetric methods to determine the content of active 
pharmaceutical ingredient (API). Both brands of the ASA tablets 
passed the BP standards for uniformity of weight and diameter, 
disintegration, friability and crushing strength. However one of the 
two brands did not comply with the standard assay of content of 
active ingredient. Thus based on these results it can be concluded 
that these two brands of ASA are not pharmaceutically equivalent. 
 




Acetyl Salicylic Acid (ASA) or Aspirin 
(Figure 1) is one of the oldest and the most 
commonly used Non steroidal anti-
inflammatory drug (NSAID). It is an effective 
analgesic, anti-inflammatory, anti-thrombotic 
and antipyretic agent, that primarily acts by 
permanently inactivating the cyclooxygenase 
(COX)-mediated activities of prostaglandins 
through irreversible binding unlike other 
NSAIDs, which are reversible inhibitors 
(Gordon et al., 1994; Patrono et al., 2001). ASA 
is rapidly and extensively absorbed by first-
order kinetics and distributed throughout the 
body fluids. Following oral administration, it is 
rapidly metabolized and excreted as salicylate 
(Rhaman et al., 1991). 
ASA is one of the safest, least expensive 
NSAID with multinational brands available on 
the market place. The various brands available 
in the market are considered pharmaceutically 
equivalent if they contain  the same  amount  of  
active ingredient in the identical dosage form 
and meet the same compendial or other 
applicable standards (i.e., strength, quality, 
purity, and identity), but may differ in 
characteristics such as shape, packaging, 
excipients (including colors, flavors, 
preservatives), expiration time, and, within 
certain limits, labeling requirements etc. [FDA 




Figure 1. Structure of Acetyl Salicylic Acid. 
 
It is the joint responsibility of the 
manufacturers and the drug law enforcing 
agencies to ensure that various marketed 
pharmaceutical products containing the same 
active ingredient in the identical dosage forms 
are uniform, safe and effective.  The  safety and  
efficacy  of  drug   products  can  be guaranteed 
when their quality is reliable and reproducible 
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from batch to batch. To ensure the requisite 
quality, drug manufacturers are required to test 
their products during and after manufacturing 
and at various intervals during the shelf life of 
the product (Chow, 1997). 
Pharmaceutical equivalent products help 
the practitioners and pharmacists in 
substitution of one brand for the other in case 
of non availability; however this substitution is 
quite controversial and is often met with 
suspicion among patients and physicians 
(Meredith, 2003). 
ASA is one of the most commonly used 
NSAID in clinical practice, therefore, it is 
necessary to monitor and ascertain the quality 
of the various brands available in the market.  
The quality i.e. safety and efficacy of solid 
dosage form  such as tablets can readily and 
satisfactorily be assessed by carrying out in- vitro 
Pharmaceutical tests. The present study was 
carried out to evaluate the pharmaceutical 
equivalence of two brands of dispersible ASA 
tablets available in Oman using in vitro methods 
as per the British Pharmacopoeia (BP) and 
unofficial standards as recommended by the 
manufacturers. The assessment of tablets 
included the evaluation of uniformity of weight 
and diameter, friability, crushing strength, 
disintegration and chemical assay by volumetric 
(visual titration) and colorimetric methods to 
determine the content of active pharmaceutical 
ingredient (API). 
 
MATERIALS AND METHODS 
Two different brands of dispersible ASA 
300 mg tablets were purchased from the retail 
pharmacy and were coded as A and B. The 
labeled shelf life was three years from the date 
of manufacturing and the tablets were 




Hardness tester Monsanto type 
(Bellstone Hi–Tech International): Friabilator 
(Bellstone Hi–Tech International); Micrometer 
screw gauge; Digital balance (Sartorius);        
Digital      tablet      disintegration     test    apparatus  
(Bellstone Hi–Tech International); Colorimeter 




Conc. Hydrochloric acid; 0.1M, 0.5M 
and 1M NaOH; Potassium chloride; 0.025 M 
Ferric chloride; 0.5 N Hydrochloric acid and 
Phenol red indicator. 
 
Methods 
Identity, uniformity of weight and 
diameter, friability, crushing strength, 
disintegration and assay for the content of 
active ingredients by titrimetry (British 
Pharmacopoeia, 2009) and colorimetry 
(Abdulkadir et al., 2009) were done as described 
in the British Pharmacopoeia and literature. All 
the assays were carried out in triplicate.  
 
Data analysis 
Data for hardness, friability, diameter, 
weight uniformity test, disintegration and 
content uniformity of the tablets were analyzed 
by determining the mean ± standard deviation. 
Student’s t test was used for determining 
significance. P values <0.05 were considered as 
significant. 
 
Hardness    
Hardness of the tablet was measured 
using Monsanto hardness tester. Ten tablets of 
each brand were randomly selected and the 
hardness of the tablets was determined (n=10).  
 
Friability 
Ten randomly selected tablets for each 
brand were initially weighed and placed in a 
friabilator chamber. The friabilator was 
operated at 25 rpm for 4 minutes (up to 100 
revolutions). Thereafter, tablets were removed, 
dusted and reweighed. The percent (%) 
friability was then calculated by using following 
formula (Kalakuntla et al., 2010). The test was 





WBT : Weight Before TestWAT : Weight After Test  
 
Diameter  
Random samples of 10 tablets were 
selected from each brand and their diameter 
was calculated in centimeters with the help of 
micrometer screw gauge. 
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Weight variation 
The weights of twenty tablets were 
determined individually using an electronic 
digital balance. The average tablet weight and 
standard deviation were calculated and 
compared with the permissible limits.  
 
Disintegration   
A 900mL beaker was filled with distilled 
water and was maintained at 37±0.5°C. Six 
tablets of each brand were selected and placed 
in each of the cylindrical tubes of the basket 
and connected to the disintegration apparatus. 
To avoid the floating of tablets while tube 
move upwards and downwards in water, discs 
were used. The time taken to break each tablet 
into small particles and pass out through the 
mesh at the bottom of the tube was recorded. 
Mean disintegration time was calculated for 
each of the brands. 
 
Content uniformity 
Acid- Base titration method: twenty tablets 
of each brand of ASA were weighed              
and crushed to powder. To a weighed            
quantity of tablet powder equivalent to 500mg 
of ASA, 30mL of 0.5M of Sodium             
hydroxide was added. The solution was boiled 
for 10min and titrated with 0.5M hydrochloric 
acid  using phenol red as an indicator till               
the color changed from red to yellow. A            
blank titration was also performed by            
omitting the sample. The difference          
between the two titrations was used to 
determine the percentage content of ASA              
in the tablets. Each 1mL of 0.5M                 
sodium hydroxide is equivalent to 45.04mg of 
ASA.  
Colorimetric analysis: A series of working 
solutions with different ASA concentrations 
were prepared and complexed with Ferric 
chloride solution.  The absorbance of each 
solution was measured at 530nm and a 
calibration curve was constructed.  Using the 
standard curve, the amount of ASA in each 
brand was determined. 
 
Standard solution of ASA  
A stock standard solution (800μg/mL) 
was prepared by dissolving 80 mg of ASA 
powder in 10mL of 1M NaOH. The solution 
was boiled, cooled and diluted to 100mL with 
purified water. Working standards for 
constructing a calibration curve were prepared 
by pipetting 10, 8, 6, 4 and 2mL aliquots of the 
stock standard solution into separate 100mL 
volumetric flasks and diluting to volume with 
0.025M FeCl3.  
 
Sample preparation 
Three ASA tablets from each brand were 
weighed individually and powdered.  Each 
powdered tablet was quantitatively transferred 
to 250mL volumetric flask and 10mL of 1M 
NaOH was added to it. Solutions were heated 
to boiling, cooled to room temperature and 
were diluted up to the mark with purified water. 
5mL aliquots of each sample were pipetted into 
separate 100mL volumetric flasks and each 
flask was diluted to volume with 0.025M ferric 
chloride solution. Absorbance of standard 
solutions and unknown was measured at 
530nm by using 0.025M FeCl3 as blank. 
 
RESULTS AND DISCUSSION  
The results of various quality control 
tests performed on two different brands of 
ASA tablets are presented in table I and table 
III. In order to determine the ASA content in 
tablets by FeCl3-colorimetric method, five 
working standard solutions were prepared and 
their absorbance was measured to construct 
standard calibration curve. A liner regression of 
the standard absorbance data of working 
solutions (Table II) in statistical software, SPSS 
gave the following equation which was used to 
determine the ASA content of analyzed tablets. 
Y = 11.155x+0.0096  (R² = 0.9912) 
Hardness of ASA tablets was found to 
be in the range of 4.5 to 6Kg/cm2 indicating 
good mechanical strength. The hardness values 
of both the brands met the pharmacopoeial 
requirement and based on the results it could 
be expected that tablets would be resistance to 
capping or breakage while handling during 
transportation and storage. However, a 
significant difference was observed in the mean 
crushing strength of the two brands by 
student’s t test. 
Weight loss due to friability in both 
marketed preparations was found to be less 
than 1% indicating that both brands are 
mechanically   stable   and  will not undergo any  
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wear or tear during transportation. Brand B 
showed more % weight loss (0.65%) than 
brand A (0.63%). However, both the brands 
met the Pharmacopoeial requirement and no 
significant statistical difference was found in 
the mean friability. 
Diameter of two brands of ASA tablets 
was well within the permissible limits 
(average±5%) and thus met manufacturer’s 
requirements for tablet diameter. Result 
suggests that they are uniform in size and 
shape. Comparison of values for both brands 
showed no difference in diameter as mean 
diameter of brand A and B was found to be 
0.806cm and 0.865cm respectively. Variance of 
two brands was also found to be similar. 
Weight uniformity test for tablets is 
required to ensure that the drug content in each 
tablet is distributed in a narrow range around 
the label strength because slight variation in 
weight of tablet reflects variation in the content 
of active ingredient. According to the BP, drug 
products whose strength is >250mg, 
permissible limit of ±5% of the average is 
required to pass the test for weight uniformity. 
Both the commercial products possessed 
acceptable uniformity of weight as per the 
pharmacopoeial  limit.   20  randomly   selected  





(n = 6) 
Friability 
(% ) 










n time (sec) 
Mean±SD 
(n = 6) 
A 6±0.1 0.63 0.806±0.015 364.41±2.29 32.3±3.01 




<0.05 0.07 <0.05 <0.05 0.846 
 
Table II. Standard Absorbance values of ASA for plotting standard curve by colorimeter 
 
Absorbance Stock concentration (mg/mL) Stock number 
0.177 0.0159 1 
0.357 0.0318 2 
0.554 0.0477 3 
0.758 0.0637 4 
0.865 0.0796 5 
 
Table III. Content uniformity assay of ASA in two brands by acid- base titration and colorimetric 
method 
 
Remarks as per the BP 
permissible limit (95-105%) 
% ASA content Content found (mg) 
Mean±SD 
Brand 
Colorimeter Titration  Colorimeter Titration  Colorimeter Titration   
Failed Failed 92.2 93.57 276.6±2.14 280.7±4.4 A 
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tablets in brand A and B were within the 
mean±5% B.P range for weight uniformity, 
(337.1-391.7) mg and (368.1-427.7) mg 
respectively. P- value for weight uniformity was 
found to be statistically significant (<0.05). 
Disintegration evaluates availability of a 
drug for dissolution and absorption from the 
Gastrointestinal tract. The results presented in 
table 1 reveals rapid disintegration of both the 
products. Fast disintegration is required for 
analgesics in order to get prompt relief. Both 
the products meet the disintegration limit set by 
the British Pharmacopoeia. According to the 
BP 2004, the time limit for disintegration of 
dispersible tablets is <3 min. Statistical analysis 
showed no significant difference in mean 
disintegration time of two brands. 
Both the brands were assayed for the 
acetyl salicylic acid content by acid base 
titration and colorimetry to study and compare 
the efficacy of analytical method in 
quantification of active constituent. Ebeshi et. 
al., in 2009 reported that a single method is not 
adequate to authenticate the quality of 
particular drug sample in post market 
surveillance, therefore, manufacturers or 
regulatory authorities should use more than one 
analytical method to evaluate the quality of 
pharmaceutical products.  
The percentage content of ASA must fall 
within 95-105% as per the official compendium 
specification for tablets with average weight 
above 250 mg (British Pharmacopoeia, 2009). 
Mean average content of analyzed ASA tablets 
by colorimetric method was found to be 92.2% 
for brand A and 100% for brand B. The 
amount of active ingredient in brand A is less 
than 95% of the labeled amount as required by 
BP, so it failed the content uniformity test by 
this method. Brand A also failed to meet the 
official compendium requirement for content 
uniformity by volumetric method of analysis. 
Mean average content of ASA in brand A 
tablets by visual acid base titration method was 
found to be 93.57%. On the other hand, brand 
B passed the content uniformity test by both 
methods as it conformed to the official limit         
of 95-105%. The p -value obtained by student’s 
t-test was found to be non significant as it was 
less than 0.05. The results obtained by two 
different methods of chemical analysis were 
almost similar, hence it could be concluded that 
any of these two methods could be employed 




Quality control is a procedure or set of 
procedures intended to ensure that a 
manufactured product or performed service 
adheres to a defined set of quality criteria or 
meets the requirements of the customer. Two 
different brands of ASA tablets were evaluated 
using quality control tests of (Hardness, 
Friability, Diameter ,Weight variation, 
Disintegration time, and content uniformity)  
with aim to assess whether these two brands 
are pharmaceutically equivalent or not. The 
results obtained were compared with British 
Pharmacopoieal standard specifications.  
The results indicated that brand B met 
all requirements of the quality control tests 
(official and unofficial), although brand A 
passed all the official and unofficial tests but 
failed the content uniformity test as its mean 
drug content was found to be outside the 
compendial tolerance limit i.e. (95-105%) by 
both the  methods of analysis.  
There is not much difference in the 
pricing of both brands and thus these are 
equally prescribed by the prescribers in Oman. 
However, results of this pilot study suggest that 
the two brands of ASA differ in the content of 
API, so are not pharmaceutically or chemically 
equivalent which warrants manufacturer and 
drug regulatory authorities to step up the 
quality control and cGMP procedures. 
 Further detailed study on large batches 
of tablets should be carried out to confirm the 
finding of this pilot study to ensure safety, 
quality and efficacy of this commonly used 
house hold drug. 
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